The pressing challenge for contemporary gene therapy is to deliver enough therapeutic genes to enough cancer cells in vivo. With the aim of improving viral distribution and tumor penetration, we explored the use of decorin to enhance viral spreading and tumor tissue penetration. We generated decorin-expressing replication-incompetent (dl-LacZ-DCNG, dl-LacZ-DCNQ and dl-LacZ-DCNK) and replication-competent (Ad-DE1B-DCNG, Ad-DE1B-DCNQ and Ad-DE1B-DCNK) adenoviruses (Ads). Point mutants of decorin gene (DCNG), DCNK and DCNQ, have a negative and moderate binding affinity to type-I collagen fibril, respectively. In both tumor spheroids and established solid tumors in vivo, tissue penetration potency of dl-LacZ-DCNG was greatly enhanced than those of dl-LacZ, dl-LacZ-DCNQ and dl-LacZ-DCNK, and this enhanced tissue penetration effect derived from decorinexpressing Ad was dependent on the binding affinity of decorin to collagen fibril. Expression of DCNG enhanced viral spread of replicating Ad, leading to improved tumor reduction and survival benefit. Moreover, the tumoricidal effects of Ad-DE1B-DCNQ and Ad-DE1B-DCNK were lessened, as the binding affinity to collagen was decreased, showing that the increased cancer cell cytotoxicity was driven by the action of decorin on extracellular matrix (ECM). Furthermore, Ad-DE1B-DCNG substantially decreased ECM components within the tumor tissue. Finally, intratumoral injection of Ad-DE1B-DCNG in primary tumor site greatly reduced the formation of B16BL6 melanoma cell pulmonary metastases in mice. Taken together, these data show the utility of decorin as a dispersion agent and highlight its utility and potential in improving the efficacy of replicating Ad-mediated cancer gene therapy.
Introduction
The inefficient ability of adenoviral vectors to disseminate throughout tumor tissues remains a major obstacle in the development of a successful cancer gene therapy. [1] [2] [3] [4] [5] [6] A number of groups are seeking to address this problem by using oncolytic adenoviruses (Ads) that selectively replicate in the tumor cells. Bischoffet al. 7 reported that by deleting an Ad early gene, E1B 55 kDa, Ad selectively proliferated in cancer cells. Subsequently, in our previous report, we have shown that E1B 19 kDa and E1B 55 kDa double-deleted replication-competent Ad, Ad-DElB19/ 55 (referred to as Ad-DE1B in this paper), induced viral cytolysis as well as E1A-mediated apoptosis, leading to an improved efficacy over E1B 55 kDa gene deleted replication-competent Ad, Ad-DElB55. 8 Overall, selective replication and viral spread within cancer cells has seen some success, but the overwhelming promise that was once projected has not been fully realized mainly because of the uneven penetration and viral distribution of these engineered Ads within the tumor tissues. To date, ONYX-015 (originally named dl1520), an E1B 55 kDa gene deleted oncolytic Ad has been tested in over 15 clinical trials on a range of tumor types, 9, 10 but has reported only limited success (7-14% local response rate) in patients with head and neck cancer, and worse, no single-agent efficacy was noted in other tumor types. 11 In preclinical xenograft tumor model studies, wild-type Ads have been shown to delay the growth of tumors, but rarely is able to eradicate established tumors. Recently, Sauthoff et al. 12 showed that high levels of titratable Ads persisted within the xenograft tumors for at least 8 weeks after intratumoral injection of the wild-type Ad, but the pattern of viral distribution within the tumor tissue was uneven and patchy. The long-term viral persistence without complete responses suggests that viral spread maybe limited, and that this limitation could be an important mechanism for the reported lack of efficacy.
Recent evidence has shown that connective tissue and extracellular matrix (ECM) may have a prominent role in inhibiting viral spread after their administration. First, Kuriyama et al. 13 showed that treatment with collagenase/dispase or trypsin before intratumoral injection of Ad enhanced virus-mediated gene transduction. Similarly, Maillard et al. 14 elevated the efficiency of Ad-mediated gene transfer by about two-fold by treating rabbit iliac arteries with elastinase, an enzyme which dissociates elastin. More recently, studies from our laboratory have shown that ECM degradation by relaxin expressed from Ads increased viral spread throughout the tumor mass, resulting in an enhancement of transduction efficiency in solid tumors in vitro and in vivo. 15 Relaxin also showed superior viral distribution of replicating oncolytic Ad, leading to an increased antitumor effect and survival advantage.
To extend our understanding of the role of the ECM barrier and connective tissue in inhibiting viral spread and penetration within tumor masses, we evaluated the utility of decorin. Decorin, a small leucine-rich proteoglycan, is a ubiquitous component of the ECM and is preferentially found in association with collagen fibrils. 16 Decorin binds to collagen fibrils and delays the lateral assembly of individual triple helical collagen molecules, resulting in the decreased diameter of the fibrils. Decorin may also affect the production of other ECM components by blocking the activity of transforming growth factor-b (TGF-b). 17 In addition, decorin can modulate the interactions of ECM components, such as fibronectin and thrombospondin, with cells. Furthermore, decorin is capable of affecting the ECM remodeling by induction of the matrix metalloproteinase collagenase-1. 16, 18 These observations suggest that decorin regulates the production and assembly of the ECM at several levels, and hence has a prominent role in remodeling connective tissues.
Given the importance of the role of decorin in the ECM remodeling, we hypothesized that an increased expression of decorin would facilitate the spread of Ads within tumor tissues. We show here that expression of decorin dramatically increased the transgene expression and functionally, the dispersion of Ads within tumor tissues. As such the oncolytic potency of a decorin-expressing replicating Ads was significantly greater, both in vitro and in vivo. Taken together, these data show the utility of decorin as a dispersion agent and suggest that decorin exhibits a high potential in improving the efficacy of replicating Ad-mediated cancer gene therapy.
Results

Construction of decorin-expressing Ads and expression pattern of decorin
To evaluate the role of decorin in altering tumor penetration efficiency, replication-incompetent dl-LacZ-DCNG, dl-LacZ-DCNQ and dl-LacZ-DCNK Ads expressing LacZ as a reporter were constructed. Tumor-specific replication-competent Ads (Ad-DE1B-DCNG, Ad-DE1B-DCNQ and Ad-DE1B-DCNK) were also constructed to enhance viral spreading into the tissues. Point mutants of decorin gene (DCNG), DCNK and DCNQ, contain substituted nucleotides at the region that has a pivotal role in binding to type-I collagen fibril. The first mutant, DCNQ, harbors a point mutation at the E180 amino acid site (E180Q), which is located in the sixth leucine-rich repeat of the wild-type decorin core protein, and has a moderate binding affinity to type-I collagen fibril. The second mutant, DCNK, also harbors an amino acid exchange at the amino acid E180 site, but is substituted with lysine, resulting in lack of binding affinity to type-I collagen fibril. 19, 20 To assess the activity of the Ads, U343 cells were infected with replication-incompetent dlLacZ-DCNG, dl-LacZ-DCNQ and dl-LacZ-DCNK Ads at 20 multiplicity of infection (MOI) or with tumorspecific oncolytic Ads Ad-DE1B, Ad-DE1B-DCNG, Ad-DE1B-DCNQ and Ad-DE1B-DCNK at 5 MOI, and the medium was then recovered for western blotting. Cells infected with dl-LacZ or Ad-DE1B as negative controls for replication-incompetent Ad and tumorspecific oncolytic Ad were revealed not to express decorin, whereas all those infected with dl-LacZ-DCNG, dl-LacZ-DCNQ, dl-LacZ-DCNK, Ad-DE1B-DCNG, Ad-DE1B-DCNQ and Ad-DE1B-DCNK showed decorin expression ( Figure 1 ).
Evaluation on spreading and penetration potency of decorin-expressing Ads to tumor tissue
To evaluate the penetration potency of decorin-expressing Ads, U343 and U87 MG tumor xenografts grown in nude mice were intratumorally injected with dl-LacZ or dl-LacZ-DCNG at 5 Â 10 8 plaque-forming units (PFUs) for three injections. At 3 days after final adenoviral injection, tumor tissue was removed and stained for expression of b-galactosidase (Figure 2a) . Although dlLacZ exhibited low level of LacZ expression and the staining region was localized to the viral injection site, dl-LacZ-DCNG showed much higher LacZ expression and the stained region was found to be widely distributed to other regions of the tumor. In comparison, both dl-LacZ-DCNK and dl-LacZ-DCNQ showed that much lower LacZ expression was present in limited areas of the tumor. These results clearly show that tissue penetration potency of dl-LacZ-DCNG is greatly enhanced than those of dl-LacZ, dl-LacZ-DCNQ and dlLacZ-DCNK, and this enhanced tissue penetration effect derived from decorin-expressing Ad is dependent on the binding affinity of decorin to collagen fibril.
To further confirm the enhanced transduction efficiency and tissue penetration potency of wild-type decorin-expressing Ads, green fluorescent protein (GFP)-expressing Ads (5 Â 10 8 PFUs of dl-GFP or dl-GFP-DCNG) were injected thrice every other day into U87 tumor xenografts established in the nude mice. At 3 days after the final injection, tumors were harvested and photographed using a confocal microscope. As shown in Figure 2b , we observed a narrow path of fluorescence in Figure 1 Representative western blot analysis of human decorin from the medium collected at day 2 after infection. The results showed a significant expression of the virally transduced decorin gene.
Adenovirus expressing decorin I-K Choi et al the tumors infected with dl-GFP, which is assumed as a needle track formed when we injected viruses into tumors. In marked contrast, we observed fluorescence in more extended area of the tumor mass treated with dl-GFP-DCNG, and was not limited to sites of injections.
Furthermore, to examine whether the enhanced transduction efficiency and tissue penetration potency of decorin-expressing Ads can also be translated to primary human tumor tissues, tumor spheroids were prepared from human patients with brain or breast cancers. The spheroids were transduced with LacZexpressing or GFP-expressing Ads (1 Â 10 7 PFUs of dlLacZ, dl-LacZ-DCNG, dl-GFP or dl-GFP-DCNG). At 3 days after viral infection, the tumor spheroids were observed under a light or fluorescence microscope. As shown in Figure 3 , LacZ or GFP expression was limited on the surface of primary tumor spheroids treated with either dl-LacZ or dl-GFP. In contrast, LacZ or GFP was strongly and widely expressed in most of the tissues of the glioma and breast primary tumor spheroids treated with either dl-LacZ-DCNG or dl-GFP-DCNG. This profile of transduction efficiency and viral spread confirmed the observations noted from the in vivo experiments using human xenograft models.
Assessment of the ability of decorin-expressing oncolytic Ad to kill tumor cells
To link that the increase in spreading of decorinexpressing Ad contributes to enhanced tumor cell killing, an in vitro cytopathic effect assay was carried out. Two human glioma cell lines (U343 and U87 MG) and human normal cell lines (CBHEL, IMR90 and WI38) were infected with dl-LacZ, Ad-DE1B, Ad-DE1B-DCNG, 8 PFUs). At 3 days after the last injection of adenoviruses, tumors were harvested and photographed with a confocal microscope. In the tumors treated with dl-GFP, we observed a narrow path of fluorescence that appeared to follow the needle track when we injected the viruses. In contract, in the tumors treated with dl-GFP-DCNG, fluorescence was distributed through the tumor mass. Original magnification, Â 100. DCNG, decorin gene; GFP, green fluorescent protein; PFU, plaque-forming unit.
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Ad-DE1B-DCNQ or Ad-DE1B-DCNK Ads at MOIs of 0.1-20 for glioma cell lines and 0.1-100 for normal cell lines, and the tumor cell killing effect was analyzed. As shown in Figure 4 , as expected, dl-LacZ had no effect in killing glioma cell lines. In contrast, Ad-DE1B-DCNG exhibited about 10-20-fold higher tumoricidal effect than did Ad-DE1B control oncolytic Ad. This result was consistent over several independent experiments, indicating that decorin expression does not decrease the replication competency of Ads and contributes to the dramatic increase in tumoricidal effect of Ads as well. Interestingly, the tumoricidal effects of Ad-DE1B-DCNQ and Ad-DE1B-DCNK were decreased on lowering the binding affinity to collagen compared with that of Ad-DE1B-DCNG. In marked contrast, Ad-DE1B-DCNG in normal cells showed no significant changes in cell killing effect compared with Ad-DE1B, highlighting the cancer specificity of this Ad.
Evaluation on antitumor efficacy of decorin-expressing oncolytic Ad in vivo
Wild-type decorin-expressing oncolytic Ad, Ad-DE1B-DCNG, was next examined for its ability to suppress the growth of human tumor xenografts, U343 and U87 MG glioma models, established in nude mice. Tumors were Figure 3 Tumor spheroids prepared from a human patient with glioma (a) and breast cancer (b). Spheroids were transduced with either dlLacZ or dl-LacZ-DCNG for glioma spheroids (1 Â 10 8 PFUs) and either dl-GFP or dl-GFP-DCNG for breast cancer spheroids (1 Â 10 7 PFUs). The glioma spheroids were photographed with a light microscope for LacZ expression at 3 days post-infection and breast cancer spheroids were photographed with a fluorescence microscope for GFP expression at 11 days post-infection. Increased gene transfer, as shown by green fluorescence or LacZ staining, was achieved with decorin-expressing adenoviruses than with the control adenoviruses. Original magnification, Â 40. GFP, green fluorescent protein; PFU, plaque-forming unit.
Adenovirus expressing decorin I-K Choi et al generated by subcutaneous injection of cells into the mice abdominal region. When tumors reached an average size of 70-100 mm 3 , 5 Â 10 8 PFUs of viral load were injected intratumorally thrice, every other day. As shown in Figure 5a , the growth of oncolytic Ad-treated tumors was substantially delayed in all human xenograft models examined. For the U343 xenograft model, the control mice treated with phosphate-buffered saline (PBS) resulted in the considerable tumor growth to 2118.17±144.96 mm 3 at day 53 posttreatment, whereas Ad-DE1B and Ad-DE1B-DCNG led to the significant suppression of tumor growth to 916.00 ± 191.78 mm 3 and 329.80 ± 126.74 mm 3 , showing 57% (Po0.001 versus PBS) and 84% (Po0.001 versus PBS; Po0.05 versus Ad-DE1B) Figure 4 Enhanced cytopathic effect of decorin-expressing oncolytic adenovirus. Cells were infected with dl-LacZ, Ad-DE1B, Ad-DE1B-DCNG, Ad-DE1B-DCNQ or Ad-DE1B-DCNK at the indicated multiplicity of infection (MOI). At 4-8 days post-infection, surviving cells were stained using crystal violet. Replication-incompetent adenovirus dl-LacZ served as a negative control. Each cell line was tested at least thrice, and data shown are from representative experiments. DCNG, decorin gene. Figure 5 Enhanced suppression of the growth of established tumors (a) and survival (b) after intratumoral injection with Ad-DE1B-DCNG compared with Ad-DE1B oncolytic adenovirus. Human glioma tumors were grown subcutaneously in the abdomen of nude mice and were subsequently injected directly with phosphate-buffered saline (PBS) (~), Ad-DE1B (}) or Ad-DE1B-DCNG (J). Tumor volume was monitored regularly after treatment. The arrow indicates when treatment was given (5 Â 10 8 PFUs). Values represent the mean ± s.e.m. (n ¼ 8 animals per group for U343; n ¼ 7 animals per group for U87 MG). There was a statistically significant enhanced antitumor effects and longer survival in Ad-DE1B-DCNG-treated mice compared with Ad-DE1B treatment (Po0.05). DCNG, decorin gene; PFU, plaque-forming unit. Figure 5b shows survival curve for PBS-treated, Ad-DE1B-treated and Ad-DE1B-DCNG-treated tumor-bearing mice. For U343 tumor-bearing mice, 53 days after the beginning of the treatment, 100% of the animals treated with Ad-DE1B-DCNG were still viable, whereas 75% of Ad-DE1B-treated mice were viable in the same time period. Similarly, Ad-DE1B-DCNG-induced survival benefits were obtained in U87 MG xenograft models. Throughout the course of the study, no systemic toxicity, such as diarrhea, loss of weight or cachexia was observed. These results show that Ad-DE1B-DCNG can confer significant survival advantage and tumor reduction in vivo.
Change of tumor characteristics induced by decorinexpressing oncolytic Ads
The enhanced antitumor effect of decorin-expressing oncolytic Ads was further investigated by histological examination. Tumors were harvested from each treatment group at 3 days after the three sequential treatments. Hematoxylin and eosin staining revealed that the majority of remaining tumor mass treated with Ad-DE1B-DCNG was necrotic, whereas necrotic lesions were only detectable in the limited region of tumors treated with Ad-DE1B (Figure 6a ). Viral distribution within the tumor mass was then confirmed by immunohistochemistry using an antibody specific to adenoviral hexon protein. Marked increase in number of adenoviral particles was detected in wider areas of Ad-DE1B-DCNG-treated U343 and U87 MG tumors in comparison with Ad-DE1B-treated tumors. To analyze the degree to which Ad-DE1B-DCNG induced apoptosis in vivo, terminal deoxynucleotidyl transferase dUTP nick end Adenovirus expressing decorin I-K Choi et al labeling (TUNEL) assay was carried out. As seen in Figure 6a , apoptotic level was significantly higher in Ad-DE1B-DCNG-treated tumor tissue than in PBS-or Ad-DE1B-treated tumor tissue, thus showing that Ad-DE1B-DCNG Ad replicates actively in the viral injection site and spreads widely, contributing to the induction of apoptosis and necrosis.
Change of ECM components in tumor mass treated with decorin-expressing Ads
Tumor section slides from the tumor-bearing nude mice treated with Ad-DE1B or Ad-DE1B-DCNG were first stained using Biebrich scarlet acid fuchsin (Masson's trichrome stain) to analyze the distribution of collagen fibers (stained blue color), a major component of extracelluar matrix. As shown in Figure 6b , U343 tumors treated with Ad-DE1B consisted of high content of collagen fibers (blue staining). In marked contrast, tumors treated with Ad-DE1B-DCNG appeared to be devoid of collagen fibers, indicating that decorin expression dramatically reduced the content of collagen fibers within the tumor mass. We further stained the tumor tissues with antibodies specific to collagen type-I, collagen type-III and elastin. All these ECM components were prominent in the PBS-treated and Ad-DE1B-treated control tumor tissues, whereas almost no immunopositivity was observed in Ad-DE1B-DCNGtreated tumors, mirroring the findings with the Massons's trichrome staining. These results closely parallel and support the increased viral spread in the tumor mass and enhanced antitumor effect of decorin-expressing oncolytic Ads.
Inhibition of tumor metastasis by decorin-expressing oncolytic Ads
As degradation of ECM has the potential to increase tumor metastasis, the impact of decorin expression on metastatic potential was examined using a spontaneous metastasis model. B16BL6 melanoma cells (1.5 Â 10 5 cells per mouse) were implanted subcutaneously to form a local primary tumor on the right hind footpad of C57BL/6 mice, and metastases to distant organs were measured after the removal of the primary tumor. As shown in Figure 7 , B16BL6 metastatic tumor nodules in the lung were considerably reduced by treatment with Ad-DE1B or Ad-DE1B-DCNG. The average number of 
Discussion
An important issue that has received little attention, but is fundamentally critical in improving viral-based cancer gene therapy, is the limited distribution of viruses within solid tumor tissues. Recent evidence has shown that connective tissue and ECM may have a prominent role in inhibiting viral spread. Harrison et al. 6 showed that even though viable replicating viruses persisted within the bulk of the tumor, the connective tissue within established tumors hindered its spread and thus blocked complete tumor eradication. Similarly, it has been shown that viral spreading is impaired by the presence of tumor-supporting structures. 12 Moreover, in a phase-I clinical trial for recurrent glioma, it has been shown that the zone of transduced cells did not extend beyond 5 mm from the site of injection. 21 To infect cells that are distally located from the site of viral inoculation, replicating Ad must transverse the extracellular space between cells and connective tissue. Therefore, strategies aimed at increasing the extent of anatomic distribution of the replicating virus within a tumor mass would be desirable and timely.
To address this issue, we explored the use of decorin to enhance viral spreading and tumor tissue penetration. The enhanced gene transfer efficiency and viral spreading of dl-LacZ-DCNG was evident in solid tumor mass in vivo, wherein intratumoral injection with dl-LacZ-DCNG resulted in much more extensive LacZ staining throughout the entire tumor tissue than that with dl-LacZ. Further, mutant decorin-expressing Ads, dl-LacZ-DCNQ and dl-LacZ-DCNK, lost their ability to enhance gene transfer efficiency and tissue penetration in tumor tissues. In accordance with these results, GFP-expressing dl-GFP-DCNG also increased viral spreading and tumor tissue penetration in U87 MG xenograft models as well as in human primary tumor tissues, confirming the decorin-mediated increase in transduction efficiency. Taken together, these lines of evidence show that decorin expression significantly enhanced the transgene expression carried by adenoviral vectors and facilitated the viral dispersion throughout the tumor tissue both in vitro and in vivo.
The role of decorin in markedly enhancing the transduction efficiency of decorin-expressing Ads (dlLacZ-DCNG and dl-GFP-DCNG) is likely because of its role in degrading the ECM of tumors/spheroids. We observed that the gene transfer efficiency of dl-LacZ-DCNG in comparison with dl-LacZ was more intensified when these engineered Ads were injected multiple times (data not shown). As tumor spheroids were cultured for 3 days in the culture medium, residual Ad can infect cells continuously into the core of the spheroid. Similarly, in vivo, established xenografts were treated repeatedly, allowing ample time for decorin to reduce the ECM content of the tumor tissue by the initial exposure, and subsequent penetration and spread of Ads by the repeated treatment. In both cases, previous exposure to dl-LacZ-DCNG seems to make the tumor environment much more favorable to subsequent viral infections.
Utilization of decorin also successfully enhanced viral spread of replicating Ad, leading to an increased antitumor effect. In cytopathic effect assay, Ad-DE1B-DCNG showed increased cell killing potency compared with Ad-DE1B. Of note, the cell killing effect of Ad-DE1B-DCNQ and Ad-DE1B-DCNK was decreased as the binding affinity to collagen was decreased, showing that the increase of cell killing effect is driven by the action of decorin on ECM. The enhanced cell killing potency of decorin-expressing Ad also translated into in vivo, as greater antitumor and survival advantage was observed for Ad-DE1B-DCNG-treated tumor-bearing mice. In particular, the antitumor activity of Ad-DE1B-DCNG in the U87 MG xenograft models was striking, as five out of seven mice underwent complete regressions. Viral persistence and distribution within tumor tissues were confirmed by immunohistochemistry, wherein a marked increase in number of adenoviral particles in Ad-DE1B-DCNG-treated tumor was detected as compared with control. Ad-DE1B-DCNG also substantially decreased ECM components within the tumor tissues, whereas normal tissue adjacent to the tumor cells was not affected. These findings provide further support for the ECM's role in inhibiting the viral spread and is Figure 7 Therapeutic efficacy of Ad-DE1B-DCNG on spontaneous pulmonary metastasis. When the B16BL6 primary tumor reached a volume of about 200 mm 3 , phosphate-buffered saline (PBS), Ad-DE1B or Ad-DE1B-DCNG was administered intratumorally thrice every other day. On day 7 after viral injection, the primary tumors were then surgically removed. On day 28 after primary tumor removal, the number of metastasized nodules in the lungs of the each mouse was counted and plotted. Each point represents the tumor nodules for every individual mouse (six mice for PBS group, seven mice for Ad-DE1B and eight mice for Ad-DE1B-DCNG) and the mean number of metastasized nodules for each group is shown with a line. *Po0.01 versus PBS-treated control and *Po0.05 versus Ad-DE1B-treated group. DCNG, decorin gene.
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consistent with what we have previously shown with relaxin. 15 Decorin has a high-affinity binding site for TGF-b, so that binding of decorin to TGF-b neutralizes its biological activity. 17 TGF-b is a pro-fibrotic cytokine that induces the accumulation of ECM by the inhibition of proteolytic enzymes and the enhancement of their tissue inhibitors. We found that TGF-b protein levels were reduced by decorin-expressing Ads (dl-LacZ-DCNG and Ad-DE1B-DCNG) not only in U343 glioma cells but also in tumor tissues, supporting the notion that decorin is a natural inhibitor of TGF-b (Supplementary data 1 and 2 ). In addition, the proteoglycan decorin is known to bind collagen fibrils near the d bands and delays the lateral assembly of collagen fibrils. 16 In accordance with these results, we observed that the level of collagen fibrils was significantly decreased in the tumor tissues treated with decorin-expressing Ad.
Finally, intratumoral administration of Ad-DE1B-DCNG did not enhance but inhibited the formation of pulmonary metastases of B16BL6 melanoma cells in mice. Treatment with Ad-DE1B-DCNG resulted in a 94% inhibition (Po0.01) of pulmonary metastases versus 80% (Po0.01) for Ad-DE1B relative to PBS treatment, suggesting that decorin-expressing oncolytic Ad can elicit potent antitumor efficacy not only against solid tumor but also against metastatic tumor lesions. TGF-b is a well known pleiotropic cytokine that exerts immunosuppressive effects in many different ways, including the inhibition of T-cell proliferation and T-cell effector functions. 22, 23 TGF-b also promotes the generation of Tregs, which results in added immunosuppression. 24 As high levels of TGF-b are produced by many types of tumors, the decorin-mediated suppression of TGF-b might contribute to the activation of an antitumor immune response, ultimately leading to better therapeutic effects in the lung metastasis model. Moreover, the therapeutic advantage of treatment with decorin-expressing oncolytic Ad showed in this study using a murine spontaneous metastatic model would be greatly enhanced in a human system, because human tumor cells are much more permissive to adenoviral infection and replication.
The pressing challenge for contemporary gene therapy is to deliver enough therapeutic genes to enough cancer cells in vivo. The application of decorin to enhance the ability of Ad to facilitate cell-to-cell dispersion resulted in significantly enhanced antitumor effect of replicating Ad in a variety of tumor xenograft models. This study is the first to report utilization of decorin to achieve therapeutic benefit with increased distribution of viral vectors in tumor tissues. In addition, we also show the usefulness of replication-incompetent Ad-mediated transfer of decorin as well as that of oncolytic Ad-mediated transfer of decorin. In summary, our findings presented here indicate that the expression of decorin may be a useful strategy in enhancing the efficacy of virus-mediated cancer gene therapy.
Materials and methods
Cell lines and cell culture U343 and U87 MG human glioma cell lines and HEK293 (human embryonic kidney cell line expressing the adenoviral E1 region) were cultured in Dulbecco's modified Eagle's medium (Gibco BRL, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Gibco BRL), L-glutamine (2 mM), penicillin (100 IU ml À1 ) and streptomycin (50 mg ml
À1
). The murine B16BL6 melanoma cells 15 were grown in minimum essential medium supplemented with 5% fetal bovine serum, vitamin solution (1 mM), sodium pyruvate (100 mM), nonessential amino acid (10 mM), penicillin (500 IU ml À1 ) and streptomycin (50 mg ml
). All cell lines were maintained 37 1C in a humidified atmosphere at 5% CO 2 .
Experimental animals
In vivo antitumor experiments were conducted using 6-to 8-week-old male nude mice (BALB/c-nu) and C57BL/6 mice purchased from Charles River Korea (Seoul, Korea). All mice were maintained in a laminar airflow cabinet under specific pathogen-free conditions. All facilities are approved by AAALAC (Association Of Assessment And Accreditation Of Laboratory Animal Care), and all animal experiments were conducted under the institutional guidelines established for the Animal Core Facility at Yonsei University College of Medicine.
Generation of decorin-expressing Ads
To generate Ads expressing decorin at the E3 region, wild-type and mutant decorin genes were first excised from pcDNA3.1-DCNG (containing the wild-type decorin cDNA), pcDNA3.1-DCNQ (containing mutant-type decorin cDNA having weaker binding affinity to collagen) and pcDNA3.1-DCNK (containing mutant-type decorin cDNA lacking binding affinity to collagen) 19, 20 using EcoRI-XbaI and the resulting 1 kb DNA fragments were subcloned into the pCA14 vector (Microbix, Ontario, Canada), generating pCA14-DCNG, pCA14-DCNQ and pCA14-DCNK vectors, respectively. The mutant decorin DCNQ harbors a point mutation of E180 amino acid to E180Q in the sixth leucine-rich repeat of the wild-type decorin core protein. The mutant decorin, DCNK, harbors an amino acid exchange at amino acid E180, which is an important site for the interaction of decorin with type-I collagen fibrils. Each of the pCA14-DCNG, pCA14-DCNQ and pCA14-DCNK vectors were digested with BamHI, and the CMVdecorin-polA expression cassettes were then subsequently cloned into the adenoviral E3 shuttle vector pSP72-E3, 25 resulting in pSP72-E3/CMV-DCNG, pSP72-E3/CMV-DCNQ and pSP72-E3/CMV-DCNK adenoviral E3 shuttle vectors. The adenoviral E3 shuttle vectors thus prepared were linearized with XmnI and cotransformed into E. coli BJ5183 together with the adenoviral total vector, pdl-LacZ, linearized with SpeI for homologous recombination, generating the replication-incompetent adenoviral vectors dl-LacZ-DCNG, dl-LacZ-DCNQ and dl-LacZ-DCNK, which express the LacZ and decorin simultaneously. We also generated tumor-specific oncolytic Ads expressing the decorin gene. Specifically, each of dl-LacZ-DCNG, dl-LacZ-DCNQ and dl-LacZ-DCNK was linearized with XmnI and cotransformed into Escherichia coli BJ5183 together with the E1B 19 kDa/ E1B 55 kDa-deleted pAdDE1B19/55 Ad vector linearized with SpeI 26 for homologous recombination, generating the Ad-DE1B-DCNG, Ad-DE1B-DCNQ and Ad-DE1B-DCNK Ad vectors, respectively. To verify the occurrence Adenovirus expressing decorin I-K Choi et al of homologous recombinants, the recombinant adenoviral vectors were digested with HindIII, and the digestion pattern was analyzed. The proper homologous recombinant adenoviral vectors were digested with PacI and transfected into 293 cells to generate Ads. All Ads were propagated in 293 cells and their titration was performed according to limited dilution assay, followed by concentration using CsCl gradient and purification. Viral particle numbers were calculated from measurements of optical density at 260 nm (OD 260 ), in which 1 absorbency unit is equivalent to 10 12 viral particles per milliliter, and infectious titers (PFUper milliliter) were determined by limiting dilution assay on 293 cells. The MOI was calculated from PFUs. The particle-to-PFU ratio for dl-LacZ, dl-LacZ-DCNG, dl-LacZ-DCNQ, dl-LacZ-DCNK, Ad-DE1B, Ad-DE1B-DCNG, Ad-DE1B-DCNQ and Ad-DE1B-DCNK were 70:1, 21:1, 38:1, 29:1, 82:1, 24:1, 46:1 and 96:1, respectively.
Assessment of decorin expression
To examine the decorin expression pattern induced by generated recombinant Ads, replication-incompetent Ads and oncolytic Ads harboring the decorin gene (dl-LacZ-DCNG, dl-LacZ-DCNQ, dl-LacZ-DCNK, Ad-DE1B-DCNG, Ad-DE1B-DCNQ and Ad-DE1B-DCNK) and dl-LacZ and Ad-DE1B Ads as negative controls were infected to U343 at 20 MOI for replicationincompetent Ads and at 5 MOI for oncolytic Ads. At 48 h after infection, the medium used was recovered and subjected to SDS-polyacrylamide gel electrophoresis. Then, the proteins on the gel were electrotransferred to polyvinylidene fluoride membrane, incubated with the primary anti-decorin antibody (AF143; R & D Systems, Minneapolis, MN, USA) and anti-b-actin antibody (Sigma, St Louis, MO, USA), and then incubated with the HRP (horseradish peroxidase)-conjugated secondary antibody (6160-05; Southern Bio Technology Associates, Inc., Birmingham, AL, USA), after which the expression patterns of decorin were revealed using the ECL detection kit (sc-2004; Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Distribution (spread and penetration) of Ads in vivo
To determine the extent of viral spreading and tumor penetration in vivo, U343 and U87 MG human glioma xenografts were established subcutaneously by injecting cells into the abdomen of 6-to 8-weekold male nude mice. Once the tumors reached to 100-200 mm 3 in volume, mice were randomized and dlLacZ, dl-LacZ-DCNG, dl-LacZ-DCNQ or dl-LacZ-DCNK Ad at 5 Â 10 8 PFUs in 50 ml was intratumorally injected into the tumors thrice, every other day. On day 3 after the last injection, animals were killed and tumors were taken, after which they were fixed in 4% paraformaldehyde at 4 1C for 4-8 h and dehydrated in 30% sucrose solution for 12 h. The dehydrated tumor tissues were embedded in O.C.T. (optimal cutting temperature) compound (Sakura Finetec, Torrance, CA, USA) and snap frozen. Observance of blue staining with a light microscopy under low power was considered positive for b-galactosidase expression. Each experiment was carried out three to four times, and data from a representative experiment are shown.
Transduction efficiency and tissue penetration of decorin-expressing Ads using primary tumor tissues from breast cancer and glioma patients Tumor tissues from breast cancer and glioma patients were freshly collected, cut into 1-2 mm sections and then plated onto HydroCell 12 Multi-well plates (Nunc, Rochester, NY, USA) after which they were cultured for 4 h in IMDM (Isocove's modified Dulbecco's medium, Gibco BRL) supplemented with 5% fetal bovine serum, 10 mM l À1 insulin and 1 mM l À1 hydrocortisone. Each of the Ads (dl-GFP or dl-GFP-DCNG for breast cancer spheroids and dl-LacZ or dl-LacZ-DCNG for glioma spheroids) at 1 Â 10 7 PFUs (breast cancer spheroids) or 1 Â 10 8 PFUs (glioma spheroids) were added into the plates containing primary tumor tissues, and incubated at 37 1C in 5% CO 2 incubator for 11 (breast cancer spheroids) and 3 (glioma spheroids) days. For the observation on penetration of Ads into the tumor spheroid, the X-gal-stained tumor spheroids were embedded in O.C.T. compound and snap frozen, followed by performing X-gal staining as described above. The glioma spheroids were observed under a fluorescence microscope.
Antitumor effects and survival rates of decorinexpressing oncolytic Ads in vivo
Tumors were implanted on the abdomens of 5-to 6-week-old male nude mice by subcutaneous injection of 1 Â 10 7 U343 and U87 MG glioma cells in 100 ml of Hank's balanced salt solution (Gibco BRL). When tumors reached a range of 70-100 mm 3 , animals were randomly assigned to one of three groups to receive PBS, Ad-DE1B or Ad-DE1B-DCNG (seven or eight mice per group). The first day of treatment was designated as day 0. Ad or PBS was administered intratumorally (5 Â 10 8 PFUs in 50 ml of PBS) on days 0, 2 and 4. Tumor growth delay was assessed by talking measurements every 2 or 3 days. The volume of tumors was calculated with the major axis and minor axis measured using a caliper: tumor volume ¼ (minor axis mm) 2 Â (major axis mm) Â 0.523. The percentage of surviving mice was determined by monitoring the death of mice (for U87 MG xenografts) or tumor growth-related events (tumor size 41500 mm 3 for U343 xenografts)
Change of metastatic potential over decorin expression using spontaneous metastasis model
To assess changes of metastatic potential over decorin expression, B16BL6 cells (1.5 Â 10 5 cells per mouse) were administered subcutaneously into the right hind footpad of 6-week-old male C57BL/6 mice (Charles River Korea) to form primary tumors. When the primary tumor reached a volume of about 200 mm 3 , animals were randomly assigned to one of three groups to receive PBS, Ad-DE1B or Ad-DE1B-DCNG (six to eight mice per group). The first day of treatment was designated as day 0, and then 5 Â 10 8 PFUs per tumor in 50 ml of PBS, mixed with Lipofectamine and Plus solution (Gibco BRL) at a 2:6 ratio or PBS was injected directly into the tumor on days 0, 2 and 4. On day 7, primary tumors were surgically removed by amputating the right hind leg below the knee under mild anesthesia. On day 28, primary tumor lesions in the lungs of the mice were assessed.
Adenovirus expressing decorin I-K Choi et al
Observation of the change of tumor characteristics induced by the administration of decorin-expressing Ads Tumor tissue was fixed in 10% formalin, embedded in paraffin and cut into 3-mm sections (Wax-it, Vancouver, Canada). Representative sections were stained with hematoxylin and eosin or with Masson's trichrome and then examined by light microscopy. We used reagents supplied by DAKO ARK (Dako, Carpinteria, CA, USA) to detect adenoviral antigens, as described previously 27 . The same paraffin slides were also used to identify apoptotic cells in tumors according to the instructions in the ApopTag kit for detecting cleaved deoxyribonucleic acids in situ with the TUNEL method. For the detection of collagen type-I, collagen type-III and elastin in tumor tissues, paraffin tumor sections were first treated with monoclonal anti-collagen type-I antibody (sc-25974; Santa Cruz Biotechnology), monoclonal anti-collagen type-III antibody (C7805; Sigma) or monoclonal antielastin antibody (E4013; Sigma), and then with goat antimouse IgG-Biotin (sc-2039; Santa Cruz Biotechnology) as a secondary antibody. Finally, diaminobenzidine/hydrogen peroxidase (Dako) was used as the chromogen substrate. All slides were counterstained with Meyer's hematoxylin.
Statistical analysis
The data were expressed as mean ± standard error of the mean (s.e.m.). Statistical comparison was made using Stat View software (Abacus Concepts, Inc., Berkeley, CA, USA) and the Mann-Whitney test (nonparametric rank sum test). The criterion for statistical significance was taken as Po0.05.
